BRADMER COMPLETES SUPPLY AGREEMENT WITH MDS NORDION

Bradmer Pharmaceuticals Inc., a biotechnology company dedicated to the development and commercialization of cancer therapies, has signed a three-year contract with MDS Nordion for the formulation development and clinical trial supply of Neuradiab in preparation for the planned multi-center clinical trial.
CNW Group